United Therapeutics Corporation
UTHR
#1088
Rank
$22.161 B
Marketcap
United States
Country
$516.68
Share price
0.23%
Change (1 day)
26.32%
Change (1 year)
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat…
Key Metrics
Trailing P/E
17.94
Forward P/E
16.67
EPS (TTM)
$27.90
Forward EPS
$30.03
Price / Book
3.34
EV / EBITDA
12.6x
Beta
0.56
Dividend Yield
—
Return on Equity
19.31%
Return on Assets
11.61%
Debt / Equity
—
Current Ratio
5.73
Gross Margin
86.14%
Operating Margin
42.23%
Net Profit Margin
41.56%
Free Cash Flow
$557.137M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 15
-1.56%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$3.183B
Latest Net Income$1.335B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare United Therapeutics Corporation with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
UTHR
No recent news available. Set FINNHUB_API_KEY to enable news.
